Biomarker: IFITM1

Histology type: endometrial stromal tumor

Country: Canada

Region: Ottawa

Study type: retrospective study

Followed up time :

Subgroup 1 name : endometrial stromal sarcoma

Subgroup 1 number: 14

Subgroup 2 name: smooth muscle neoplasms

Subgroup 2 number: 20

Conclusion: IFITM1 may be a valuable tool as part of an immunohistochemical evaluation panel in this diagnostic scenario.（ differentiating low-grade ESSs from smooth muscle neoplasms）

Sample type : tissue

Sample method: immunohistochemistry

Expression pattern : staining pattern(positive (score 3-6) or negative (score 0-2).)

Expression elevation: Immunohistochemical slides were reviewed and scored in terms of intensity and distribution as follows:(1) Intensity: 0= absent staining, 1 = weak staining,2= moderate staining, 3= strong staining.(2) Distribution: 0 = absent staining, 1= < 50% oftissue, 2= 50% to 75% of tissue, 3 =>75% of tissue staining.

Funtion Uniprot: IFN-induced antiviral protein which inhibits the entry of viruses to the host cell cytoplasm, permitting endocytosis, but preventing subsequent viral fusion and release of viral contents into the cytosol. Active against multiple viruses, including influenza A virus, SARS coronaviruses (SARS-CoV and SARS-CoV-2), Marburg virus (MARV), Ebola virus (EBOV), Dengue virus (DNV), West Nile virus (WNV), human immunodeficiency virus type 1 (HIV-1) and hepatitis C virus (HCV) (PubMed:26354436, PubMed:33270927). Can inhibit: influenza virus hemagglutinin protein-mediated viral entry, MARV and EBOV GP1,2-mediated viral entry and SARS-CoV and SARS-CoV-2 S protein-mediated viral entry. Also implicated in cell adhesion and control of cell growth and migration (PubMed:33270927). Inhibits SARS-CoV-2 S protein-mediated syncytia formation (PubMed:33051876). Plays a key role in the antiproliferative action of IFN-gamma either by inhibiting the ERK activation or by arresting cell growth in G1 phase in a p53-dependent manner. Acts as a positive regulator of osteoblast differentiation. In hepatocytes, IFITM proteins act in a coordinated manner to restrict HCV infection by targeting the endocytosed HCV virion for lysosomal degradation (PubMed:26354436). IFITM2 and IFITM3 display anti-HCV activity that may complement the anti-HCV activity of IFITM1 by inhibiting the late stages of HCV entry, possibly in a coordinated manner by trapping the virion in the endosomal pathway and targeting it for degradation at the lysosome (PubMed:26354436).

UniProt ID: P13164

UniProt Link: https://www.uniprot.org/uniprotkb/P13164/entry

Biological function from UniProt: Antiviral defense, Immunity, Innate immunity, Osteogenesis

Molecular function from UniProt:

Tissue specificity from UniProt: Bone (at protein level). Levels greatly elevated in colon cancer, cervical cancer, esophageal cancer and ovarian cancer. Expressed in glioma cell lines.

Subcellular UniProt: #Cell membrane #Lysosome #Membrane

Alternative name from UniProt:

Gene name from HGNC: IFITM1 (9-27, CD225, DSPA2a, IFI17)

CD antigen name: CD225

Induction: By IFN-alpha and IFNG/IFN-gamma.

HPA link: https://www.proteinatlas.org/ENSG00000185885-IFITM1

Tissue specificity RNA from HPA: Low tissue specificity

Tissue expression from HPA: Distinct membranous expression in epididymis, also expressed in endothelial cells and in lymphoid tissue.

Subcellular summary HPA Located in Golgi apparatus, Plasma membrane, Cytosol (Single cell variability)

Cancer prognostic summary HPA Prognostic marker in renal cancer (unfavorable)

Pathology link: https://www.proteinatlas.org/ENSG00000185885-IFITM1/pathology

Pathology endo: https://www.proteinatlas.org/ENSG00000185885-IFITM1/pathology/endometrial+cancer

OMIM: 604456

OMIM link2: https://www.omim.org/entry/604456

HGNC ID: HGNC:5412

HGNC link: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5412